All In Biotech

Drug Trial Radar · NCT06961344

An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

An Open-label Extension Study Evaluating the Safety of Zagociguat in Participants With MELAS Who Completed TIS6463-203

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

37

Actual

Start

Aug 18, 2025

Primary completion

Oct 29, 2026

Study completion Oct 29, 2026

Sponsor

Lead sponsor
Tisento TherapeuticsIndustry
Sponsor type
Industry
First posted
May 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study at the daily dose of 15mg. The study medication is a once daily oral table and will be provided at the clinic and/or shipped to the participant's home. Study assessments will be conducted during clinic visits which will occur at three months and then at six months. Thereafter, clinic visits will occur every six months.

Conditions

  • Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

Interventions

  • zagociguat 15mgDrug

    once daily oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through the Follow-up for treatment period 4 weeks after last dose of study medication.

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • UC San Diego - Altman Clinical and Translational Research Institute

    La Jolla, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • Rare Disease Research

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mount Sinai - Ichan School of Medicine

    New York, New York

  • Akron Children's Hospital

    Akron, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • UT Health Houston

    Houston, Texas

  • Neuroscience Research Australia

    Sydney, New South Wales, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • LMU Klinikum, Friedrich-Baur-Institute, Department of Neurology

    Munich, Germany

  • Neurologic Institute Carlo Besta of Milan

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli

    Rome, Italy

  • University College London Hospital. The National Hospital for Neurology and Neurosurgery, Centre for Neuromuscular Diseases

    London, United Kingdom

  • The Newcastle upon Tyne NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.